September 30, 2020 -- Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale production of Escherichia coli-derived recombinant proteins for cell and gene-modified therapy workflows.
Chimeric antigen receptor (CAR) T-cell therapies and stem cell therapies have significantly increased the demand for GMP-grade recombinant proteins, which Bio-Techne plans to meet with the opening of the facility. The company invested $50 million to build and outfit the plant with advanced manufacturing and quality control technologies.
The facility houses multiple fermenters and purification suites and is expected to begin commercial production in early 2021, following validation procedures.